Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/18—Peptides; Protein hydrolysates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/07—Tetrapeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Definitions

• TITLE USE OF PEPTIDE CONJUGATES FOR THE PREPARATION OF COMPOSITIONS FOR THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA
• the invention relates to the use of peptide conjugates containing the Gly-His-Lys sequence for the preparation of dermatological or cosmetic compositions for stimulating hair growth or slowing hair loss.
• hair growth and renewal is determined by the activity of - hair follicles. They carry out a regular cycle made up of ' three phases: anagen, catagen and telogen, which are each characterized by very precise molecular and cellular mechanisms: - During the anagen phase which lasts approximately three years, the cells of the dermal papilla "send" signals to stem cells present in the bulb. The competent cells which receive these signals then migrate to the matrix of the hair follicle, this is called matrix cells. In this area, the cells of the dermal papilla emit additional signals which allow the matrix cells to proliferate at first and then to differentiate which allows the elongation of the hair shaft.
• telogen a phase characterized by one inactivity of the hair follicle for three months and the fall of the hair before a new entry into the anagen phase.
• hair loss is a real problem which can be experienced as a social handicap by certain people. In humans, it is in most cases androgenic alopecia. This type of alopecia is therefore due to a defect in the catabolism of androgens and more specifically of testosterone in the hair follicle by the cells of the dermal papilla. Indeed, there is accumulation of a metabolite of testosterone, the
• DHT (metabolite which is produced by the action of 5 ⁇ - reductase on testosterone), in the hair follicles. In a normal process, this compound is broken down and then eliminated in the urine.
• 5 ⁇ -reductase inhibitors are used in this type of alopecia to slow hair loss.
• the subject of the present invention is therefore the use of a peptide corresponding to the general formula (I) X-Gly-His-Lys-Y (I) (SEQ ID No. 1-2)
• A represents the radical corresponding to a monocarboxylic acid of general formula (III) HOOC-R (III) in which R represents a linear or branched C1-C24 aliphatic radical, optionally substituted by a hydroxy group, which may contain one or more unsaturations, advantageously from 1 to 6, - lipoic acid or its reduced form, dihydrolipoic acid, N-lipoyl-lysine or also retinoic acid,
• X represents a chain of 1 to 3 Lys residues, optionally methylated or, in the case of formula (II), a bond,
• Y represents a group -OH or -NH2, the amino acids being in D, L or DL form,
• A-X represents a hydrogen atom
• the peptide sequence _ is chemically or physically conjugated with the acids A.
• the conjugated peptides according to the invention are linked in the form of salts, esters or amides to these acids A, the carboxylic acid fraction of the acid providing liaison.
• the amino acids in the peptide of formula (I) or the peptide conjugate of formula (II) can have a D, L or DL configuration.
• the peptides of formula (I) and the peptide conjugates of formula (II) may contain one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including racemic mixtures are part of the invention.
• the peptide conjugates of formula (II) are low molecular weight derivatives which are obtained in the form of amides of the compound of formula (III).
• peptides of formula (I) and the peptide conjugates of formula (II) can be coupled with zinc, in the form of a salt, to form complexes.
• the peptides and their peptide conjugates, as well as their synthesis, are described in European patent EP 869 969. They are described there as being useful in the treatment in topical application of the healing of chronic wounds, the aesthetic healing of surgical wounds , preventive and curative treatment of stretch marks and their complications. Their use in the field of cosmetology, in particular the preventive and curative treatment of facial, neck and hand wrinkles, is also disclosed. In the context of the present invention, the following definitions are intended:
• lysine or a halogen derivative of lysine, such as dihydrobromo-methyl-lysine,
• peptides of formula (I) or the peptide conjugates of formula (II) mentioned above and the use of which is the object of the present invention can be obtained in the NH2 terminal form (in other words having an amide function) and in the OH terminal form (in other words having a carboxylic acid function).
• the acid of formula (III) is a polyunsaturated fatty acid, that is to say comprising from 1 to 6 unsaturations. Even more preferably, it is an omega-3 acid.
• these omega-3 acids mention may in particular be made of ⁇ -linolenic acid, cervonic acid, timnodonic acid and pinolenic acid.
• Cervonic, timnodonic and pinolenic acids are also known under the respective names of 4,7,10,13,16,19- docosahexaenoic acid (DHA), 5,8,11,14,17- eicosapentaenoic acid (EPA) ) and 5,9,12- octodecatrienoic acid.
• A represents a monocarboxylic acid of general formula (III)
• it can be advantageously chosen from acetic acid, myristic acid, palmitic acid, hydroxydecenoic and decenoic acids and in particular, trans-10-hydroxy acid - ⁇ 2- decenoic acid and trans-oxo-9-decene-2-oic acid.
• peptide conjugates of the invention the following peptide conjugates may be cited: 1- A-MeLys-Lys-Lys-Gly-His-Lys-NH2 (SEQ ID No. 5), 2- A-MeLys-Lys-Gly -His-Lys-NH2 (SEQ ID N ° 6), 3- A-MeLys-Gly-His-Lys-NH2 (SEQ ID N ° 7),
• the peptide conjugates for which A is chosen from lipoic acid and acetic acid are very particularly suitable, in the context of the present invention. Mention may also be made of the following peptide conjugates: peptide R H-Gly-His-Lys-OH, peptide S Lipoyl-Lys-Gly-His-Lys-NH2, peptide V Ac-Lys-Gly-His-Lys-NH2.
• the peptides or their peptide conjugates can be administered for cosmetic use topically. They can also be used in food supplements, in other words in the nutraceutical field, orally. They are preferably administered topically.
• the peptide conjugate can be present, in a topical cosmetic composition, at a concentration between 10 "8 and 10 " 3M, preferably between 10 "7 and 10 " 5 M.
• the cosmetic or dermatological composition may for example be in the form of a lotion, a treating shampoo, a spray, a gel or a treating cream.
• Another object of the present invention relates to the cosmetic treatment method for combating hair loss comprising the application to the scalp of a composition comprising a peptide conjugate described above, optionally in combination as described below.
• esters of nicotinic acid - anti-inflammatory agents, more particularly peptides with anti-inflammatory activity
• peptides or peptide conjugates can also be associated with the peptides or peptide conjugates whose use is the subject of the present invention. They correspond to the formulas W-Lys-Asp-Val-Z (I) (SEQ ID N ° 15-16) or its peptide conjugate corresponding to the formula (II) AW-Lys-Asp-Val-Z (II) (SEQ ID No. 17-18) in which A has the same definition as that given above, and W represents
• W represents Gly-Gln-Gln or Glu-Gin, when Z represents
• DOPA dihydroxyphenylalanine and by HomoPhe 1 'homophenylalanine.
• one or more UVB filters can also be associated with the peptides or peptide conjugates whose use is the subject of the present invention, when it is a topical administration. They allow photoprotection of the scalp.
• suitable UVB filters we can cite, under their INCI name:
• the peptides and peptide conjugates whose use is the subject of the invention have been the subject of pharmacological tests making it possible to show their anti-hair loss activity.
• Example 1 Lotion comprising the peptide conjugate Ac-Lys-Gly-His-Lys-NH2 (in g) - Peptide Ac-Lys-Gly-His-Lys-NH2 5.10 "6 - Ethanol at 95 ° 60 - Propylene glycol 10 Water - preservatives - perfume qs 100
• Example 2 Lotion comprising the Lipoyl-Lys-Gly-His-Lys-NH2 peptide conjugate (in g)

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Birds (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=33548254

Family Applications (1)

Country Status (7)

Cited By (5)

Families Citing this family (9)

Family Cites Families (18)

• 2003
  • 2003-07-18 FR FR0308801A patent/FR2857597B1/fr not_active Expired - Lifetime
• 2004
  • 2004-07-16 WO PCT/FR2004/001879 patent/WO2005009456A2/fr not_active Ceased
  • 2004-07-16 US US10/565,007 patent/US7507719B2/en not_active Expired - Lifetime
  • 2004-07-16 ES ES04767703T patent/ES2401686T3/es not_active Expired - Lifetime
  • 2004-07-16 CA CA2532679A patent/CA2532679C/fr not_active Expired - Lifetime
  • 2004-07-16 EP EP04767703A patent/EP1663285B1/fr not_active Expired - Lifetime
  • 2004-07-16 JP JP2006519970A patent/JP2007516209A/ja active Pending
• 2012
  • 2012-08-10 JP JP2012178403A patent/JP6006582B2/ja not_active Expired - Lifetime
• 2015
  • 2015-02-06 JP JP2015022587A patent/JP6149053B2/ja not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events